

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. K... Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHA NAND
MICHAEL PHILLIPPS
LISA M. DIROCCO
HATHAWAY P. RUSSELL
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
PETER A. DIMATTIA
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
CYNTHIA M. SOROCKI
PETER W. DINI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFIELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.

* Admitted in NY only
** Admitted in TX only

May 8, 2002

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 09/528,031
Title: *Novel Multidrug Resistance-Associated Polypeptide*
Filed: March 17, 2000
Inventor: Andrew Shyjan
Attorney Docket No. MNI-056CPCN

RECEIVED

MAY 28 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement (in duplicate);
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449 (12); and
4. Return postcard.

Please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. *For this purpose, a duplicate of this sheet is attached.*

Certificate of First Class Mailing (37 CFR 1.8(a))	
I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:	
May 8, 2002	Date
Debra J. Milasincic, Esq., Reg. No. 46,931	

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Andrew Shyjan

Serial No.: 09/528031

Filed: March 17, 2000

For: *Novel Multidrug Resistance-Associated Polypeptide*

Attorney Docket No.: MNI-056CPCN

Group Art Unit: 1642

Examiner: B. Brumback

RECEIVED

MAY 28 2002

Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER 1600/2900

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

May 8, 2002

Date of Signature and of Mail Deposit

By:

Debra J. Mhasincic, Esq.
Reg. No. 46,931
Attorney for Applicant

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicant and his attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A full copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

05/24/2002 HNCNHN1 00000105 120080 09528031


01 FC:126

180.00 CH

Inasmuch as this Information Disclosure Statement is being filed after January 2, 2002, the mailing date of the first office action in the instant application, please charge the \$240.00 fee pursuant to 37 CFR §1.97(c)(2) and §1.17(p) to our Deposit Order Account No. 12-0080 for the processing of this Supplemental Information Disclosure Statement. *For this purpose, a duplicate of this statement is also enclosed.*

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicant

28 State Street
Boston, MA 02109
(617) 227-7400

Date: May 8, 2002

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80 LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MNI-056CPCN	SERIAL NO. 09/528033
		APPLICANT Shyjan, Andrew	RECEIVED MAY 28 2002 TECH CENTER 1600/2900
		FILING DATE March 17, 2000	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

B1	✓	Genbank® Accession Number U83661 Human multidrug resistance-associated protein homolog (MRP5) mRNA, partial cds. 27-SEP-1997;
B2	✓	Genbank® Accession Number 2439974 multidrug resistance-associated protein homolog [Homo sapiens] 26-SEP-1997;
B3	✓	Genbank® Accession Number U83661 Human multidrug resistance-associated protein homolog (MRP5) mRNA, partial cds. 02-OCT-1997;
B4	✓	Genbank® Accession Number AAB71758 multidrug resistance-associated protein homolog [Homo sapiens] 01-OCT-1997;
B5	✓	Genbank® Accession Number U83661 Homo sapiens multidrug resistance protein 5 (MRP5) mRNA, complete cds. 03-AUG-1999;
B6	✓	Genbank® Accession Number AAB71758 multidrug resistance protein 5 [Homo sapiens] 03-AUG-1999;
B7	✓	Genbank® Accession Number U83661 Homo sapiens multidrug resistance protein 5 (MRP5) mRNA, complete cds. 03-AUG-1999;
B8	✓	Genbank® Accession Number AAB71758 multidrug resistance protein 5 [Homo sapiens] 03-AUG-1999;
B9	✓	Genbank® Accession Number U83661 Homo sapiens multidrug resistance protein 5 (MRP5) mRNA, complete cds. 21-JUN-2000;
B10	✓	Genbank® Accession Number AAB71758 multidrug resistance protein 5 [Homo sapiens] 21-JUN-2000
B11	✓	Wijnholds et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7476-81; and
B12	✓	Kool et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997 Aug 15;57(16):3537-47.

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY OF PAPERS
ORIGINALLY FILED